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Abstract
Purpose of Review Chronic non-bacterial osteomyelitis
(CNO) with its most severe form chronic recurrent multifocal
osteomyelitis (CRMO) is an autoinflammatory bone disorder.
We summarize the clinical presentation, diagnostic ap-
proaches, most recent advances in understanding the patho-
physiology, and available treatment options and outcomes in
CNO/CRMO.
Recent Findings Though the exact molecular pathophysiolo-
gy of CNO/CRMO remains somewhat elusive, it appears like-
ly that variable defects in the TLR4/MAPK/inflammasome
signaling cascade result in an imbalance between pro- and
anti-inflammatory cytokine expressions in monocytes from
CNO/CRMO patients. In this context, we present previously
unpublished data on cytokine and chemokine expression in
monocytes and tissues.
Summary CNO/CRMO is an autoinflammatory bone disorder
resulting from imbalanced cytokine expression from innate
immune cells. Though the exact molecular pathophysiology
remains unclear, variable molecular defects appear to result in
inflammasome activation and pro-inflammatory cytokine ex-
pression in monocytes from CNO/CRMO patients. Recent
advances suggest signaling pathways and single molecules
as biomarkers for CNO/CRMO as well as future treatment
targets.
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Introduction
Chronic non-bacterial osteomyelit is (CNO) is an
autoinflammatory bone disorder mostly affecting children
and adolescents [1–3]. Autoinflammatory disorders are char-
acterized by an activation of the innate immune system in the
absence of high-titer autoantibodies and (at least initially) no
involvement of autoreactive lymphocytes. Several genetically
inherited monogenic autoinflammatory conditions include
early-onset non-infectious osteomyelitis, namely, Majeed syn-
drome, deficiency of interleukin-1 receptor antagonist
(DIRA), and pyogenic arthritis, pyoderma gangrenosum, and
acne syndrome (PAPA). Though sharing clinical and patho-
physiological features with sporadic CNO, this manuscript
will only briefly discuss monogenic autoinflammatory bone
disorders and mainly focus on CNO.
Sporadic CNO covers a wide clinical spectrum from rather
mild, time-limited, monofocal bone inflammation to severe
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chronically active or recurrent multifocal bone inflammation.
These most severe presentations are referred to as chronic
recurrent multifocal osteomyelitis (CRMO). All ethnicities
from all geographic regions can be affected. While highest
disease incidences appear to exist in Western countries, par-
ticularly Central and Northern Europe, it remains unclear
whether reporting issues may play a role, since no global
epidemiologic studies have been performed. A genetic predis-
position for CNO has been suggested by familial clusters of
CNO patients [4–6] and associations with other inflammatory
conditions, including inflammatory bowel disease, acne, an-
kylosing spondylitis, and psoriasis (Fig. 1) [1, 2, 7, 9–13]. In
adults, patients with sporadic CNO are usually diagnosed with
SAPHO, a symptom complex of synovitis, acne, pustulosis,
hyperostosis, and osteitis [9, 10]. Thus, SAPHO is currently
seen as a closely related disorder with additional symptoms in
the adult age group.
Clinical Presentation and Epidemiology
Clinical presentation and severity of CNO vary significantly
between individual patients, covering a wide spectrum with
asymptomatic or mild inflammation of single bones at the one
end, and chronic recurrent multifocal, and sometimes bone
destruction causing osteomyelitis at the other end (then re-
ferred to as chronic recurrent multifocal osteomyelitis,
CRMO). CNO/CRMO most frequently involves metaphyses
of long bones, the pelvic bones, the vertebral column, or the
shoulder girdle/clavicle [3, 7, 12].
Clinical signs of bone inflammation include localized skin
redness (rare), warmth and/or swelling, and pain. Additional
symptoms may be caused by paraosseous inflammation, in-
volving peripheral nerves and/or vessels, skin or bowel in-
flammation, and synovitis. A subset of CNO patients exhibit
inflammatory organ involvement, including psoriasis and
palmoplantar pustulosis (~ 8%), inflammatory bowel disease
(~ 10%), and severe acne (~ 10%) (Fig. 1) [7]. Some CNO
patients develop sacroiliitis, and some patients may progress
from childhood CNO to spondylarthropathies in later life
stages [14]. In adults, skin inflammation is significantly more
common as compared to children. As mentioned above, acne
and/or palmoplantar pustulosis frequently occur in the context
of synovitis, hyperostosis, and osteitis, which is then referred
to as SAPHO syndrome.
Epidemiological data in CNO/CRMO are sparse, and in-
clude small case series and regional cohorts. CNO primarily
affects children and adolescents, but can generally occur in all
age groups. The peak onset of the disease is between 7 and
12 years of age [1–3, 9]. Chronic non-bacterial osteomyelitis
is one of the most common autoinflammatory bone disorders
in central Europe. According to several case series, CNOmay
be almost as common as infectious osteomyelitis [7, 15–17].
However, secondary to sometimes rather mild and unspecific
clinical symptoms, CNO may be missed.
Diagnostic Approach
In the absence of widely accepted diagnostic criteria and dis-
ease biomarkers, CNO/CRMO remains a diagnosis of exclu-
sion. Clinical signs include bone pain, local swelling, rarely
skin redness and heat, associated skin manifestations (includ-
ing palmoplantar pustulosis, psoriasis, and acne), sometimes
mildly elevated temperatures, and pathological fractures (usu-
ally of affected vertebral bodies). Non-infectious arthritis can
be present in up to 30% of patients [3, 7]. Routine inflamma-
tory parameters (WBC, white blood cell count; CrP, C-
reactive protein; ESR, erythrocyte sedimentation rate) are usu-
ally normal or mildly elevated.
Imaging techniques are centrally important for diagnosing
CNO/CRMO and excluding differential diagnoses [7].
Inflammatory bone lesions may be detected in plain radio-
graphs as radiolucent, osteolytic, or sclerotic lesions
[18–21], but may remain normal in early stages. Particularly
in early disease, magnetic resonance imaging (MRI) tech-
niques are highly sensitive. They can detect bone edema even
before bone erosions and sclerosis develop, and help assessing
inflammation of surrounding tissues. Strongly T2-weighted
sequences (Turbo Inversion Recovery Measurement, TIRM)
and/or gadolinium-enhanced T1 sequences with fat saturation
are used to identify inflammatory bone lesions and/or
periosseous affections [21–25]. At the time of diagnosis,
whole body imaging using MRI techniques (TIRM) should
be performed to identify clinically silent lesions, particularly
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Fig. 1 Inflammatory organ involvement in CNO/CRMO. Psoriasis and
palmoplantar pustulosis (~ 8%), inflammatory bowel disease (~ 10%),
severe acne (~ 10%), and ankylosing spondylitis (~ 25%) have been
demonstrated associated with CNO/CRMO [7, 8]. (Figure modified
after [8])
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in the vertebral column [24] (Fig. 2). MRI imaging techniques
are also essential for the assessment of disease activity during
follow-up, and the identification and monitoring of disease-
associated sequelae, which may include fractures, inflamma-
tory involvement and tissue damage to surrounding structures
[24].
In unclear cases, bone biopsies are usually performed to
exclude chronic infection, malignancies, or other systemic
disease. Important differential diagnoses include malignancies
(leukemia, lymphoma, primary and secondary bone tumors),
infections (bacterial osteomyelitis, tuberculosis, etc.), immu-
nodeficiency (e.g., defects in the IL-12: interferon axis that
may be accompanied by mycobacterial infections),
Langerhans cel l h is t iocytos is (LCH), and other
autoinflammatory disorders (e.g., Majeed syndrome [26–30],
DIRA [31], or PAPA [9]). Disease onset before 2 years of age
is extremely uncommon and should prompt considering dif-
ferential diagnoses.
Mechanisms of Chemokine and Cytokine
Dysregulation in CNO/CRMO
Despite recent scientific achievements, the exact molecular
pathophysiology of CNO is only incompletely understood.
Generally, familial (or monogenic) diseases including CNO
as a descriptive symptom can be differentiated from the entity
of sporadic CNO, by other disease features. Though not the
main focus of this manuscript, studies on monogenic/familial
forms of “CNO” contributed to the pathophysiological under-
standing of sporadic CNO/CRMO.
Familial/Monogenic CNO
There are at least three human diseases involving chronic
multifocal sterile osteomyelitis that are caused by single gene
mutations: (i) Majeed syndrome (LPIN2 mutations), (ii) defi-
ciency of interleukin-1 receptor antagonist (DIRA, mutations
in IL1RN) [26, 32, 33], and (iii) pyogenic arthritis, pyoderma
gangrenosum, and acne syndrome (PAPA, mutations in
PSTPIP1).
Majeed syndrome is characterized by early-onset multifo-
cal osteomyelitis, dyserythropoietic anemia, and joint contrac-
tures. It is caused by loss of function mutations in the LPIN2
gene, encoding for the lipin 2 protein, a phosphatidate phos-
phatase (PAP) that plays a role in lipid metabolism. Lipin2-
deficient monocytes produce high amounts of pro-
inflammatory cytokines IL-6 and TNFα when stimulated by
saturated fatty acids. Overexpression of LPIN2 on the other
hand reduces inflammatory cytokine levels [34]. For Majeed
syndrome, there is evidence that it is an IL-1β-mediated dis-
ease, since bone inflammation and serum inflammation
markers improve in response to IL-1β blockade, while
TNFα blockers have almost no effect [35].
Deficiency of IL-1 receptor antagonist is characterized by
early-onset destructive sterile bone lesions (osteitis and peri-
ostitis) and sterile pustulosis of the skin. If left untreated,
DIRA leads to a severe systemic inflammatory response syn-
drome and respiratory failure [32] due to the lack of functional
IL-1 receptor antagonist and subsequently uncontrolled IL-1β
signaling. Treatment with recombinant IL-1 receptor antago-
nist results in prompt amelioration and disease control [32,
36].
Pyogenic arthritis, pyoderma gangrenosum, and acne are
caused by mutation in the PSTPIP1 gene, involved in regula-
tion of the actin cytoskeleton. PSTPIP1 binds to pyrin, a cen-
tral negative regulator of the NLRP3 inflammasome.
Therapeutic options for PAPA are local and/or systemic ste-
roids, TNFα blockers, and IL-1 blocking agents [9, 37].
“Sporadic” CNO/CRMO
Genetic predisposition appears likely to be involved in the
pathophysiology of “sporadic” CNO. It was suggested by rare
familial clusters of CNO/CRMO and high incidences of
comorbid-affiliated inflammatory conditions such as psoriasis
and inflammatory bowel disease in CNO patients and first-
degree family members (approximately 50%) [7, 13]. Thus,
the pathophysiology and inheritance of “sporadic” CNO ap-
pears to be complex with, e.g., a combination of associated
risk alleles or individually variable (currently unknown) ge-
netic causes resulting in disease resulting in clinically related
phenotypes in the absence or presence of environmental
factors.
A tight balance between pro- and anti-inflammatory signals
is essential for immune homeostasis. Cytokines and
chemokines play key roles in controlling inflammation and
instructing immune responses. Consequently, dysregulation
of their expression is linked with susceptibility to infectious
and autoimmune diseases. It has become increasingly clear
that appropriate temporal/spatial expression of cytokines and
chemokines may be the key to the delicate balance between
inflammation and immunoregulation. The mechanisms that
govern the cell type- and receptor-specific induction of cyto-
kines and chemokines, however, in most instances remain
unclear [38, 39]. Our current pathophysiological understand-
ing of CNO/CRMO is based on a profound imbalance be-
tween pro- and anti-inflammatory cytokines [40, 41••, 42,
43] (Fig. 3). We demonstrated that monocytes from CRMO
patients fail to express the immune regulatory IL-10 in re-
sponse to Toll-like receptor (TLR)4 stimulation with lipopoly-
saccharide (LPS) [42, 43]. Impaired IL-10 expression is (at
least partially) caused by reduced activation of mitogen-
activated protein kinases (MAPK), ERK1 and 2 [42], resulting
in impaired activation and nuclear shuttling of the
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transcription factor signaling protein (SP-)1, and subsequently
altered recruitment of Sp-1 to the IL10 promoter. Furthermore,
attenuated ERK activation results in reduced histone H3S10
phosphorylation at the IL10 promotor [42, 43], an activating
epigenetic modification. Disturbed epigenetic remodeling and
reduced transcription factor binding to the IL10 promoter re-
sult in impaired IL-10 expression and a disruption of balanced
pro- and anti-inflammatory cytokine expression.
Together with its homologs IL19 and IL20, the IL10 gene is
organized in the so-called IL10 cytokine cluster on chromo-
some 1q32. IL-10 and IL-19 mostly bear immune regulatory
functions, while IL-20 exerts pro-inflammatory properties
[41••]. Thus, we asked whether the expression of IL-19 and
IL-20 are also altered in monocytes from CNO/CRMO pa-
tients. In analogy to IL10, IL19 is regulated by Sp-1 and epi-
genetic remodeling which are altered in monocytes from
CRMO patients (H3S10 phosphorylation, DNAmethylation),
contributing to reduced IL-19 expression in monocytes from
CRMO patients [41••].
Notably, the expression of pro-inflammatory IL-20 was not
reduced. Contrary, after LPS stimulation, IL-20 expression
eca
db  
*
Fig. 2 Magnetic resonance imaging in CNO/CRMO.Magnetic resonance
imaging in a 15-year-old male patient with swelling and warmth over right
mandible. a Transversal TIRM sequences unveiled bone swelling and
edema of the right mandible (arrow). b Native and c contrast-enhanced
transversal T1 sequences with fat saturation unveiled new bone formation
(arrows), resulting swelling, and in c enhancement in the right mandible
(asterisk). d Coronary T1 sequences with fat saturation in the same patient.
e Whole body MRI (coronary TIRM sequences) unveiled additional sites
of bone inflammation at both proximal humeri and the right upper iliac
spine (circles) (MRI images with friendly permission from Gabriele Hahn,
Pediatric Radiology, Medizinische Fakultät Carl Gustav Carus, Technische
Universität Dresden, Dresden, Germany)
Fig. 3 Molecular pathophysiology of CNO/CRMO. Inflammation is a
potent and undirected defense mechanism against exogenous pathogens
or endogenous danger signals (such as infections, tissue damage). The
sensing of danger signals occurs by pattern recognition receptors (PRRs),
such as the membrane-associated Toll-like receptors (TLRs) and the pre-
dominantly cytoplasmic localized NOD-like receptors (NLRs). After rec-
ognition of danger signals by monocytes/macrophages, multiprotein
complexes, referred to as inflammasomes are activated. The NLRP3
inflammasome comprises NLRP3, ASC, and procaspase-1. After
inflammasome activation, caspase-1 cleaves pro-IL-1β and leads to the
secretion of active IL-1β. In monocytes from CRMO patients, MAP
kinase Erk1 and 2 signaling is impaired, resulting in reduced expression
of the immune regulatory cytokines IL-10 and IL-19. JNK and p38
MAPK are unaffected, leading to the expression of pro-inflammatory
cytokines (TNFα, IL-6, IL-1β, IL-20). Reduced expression of IL-10
and IL-19 contributes to increased inflammasome activation and subse-
quent IL-1β release. Pro-inflammatory cytokines TNFα, IL-6, IL-20, and
IL-1β increase the interaction of membrane RANK receptors with their
soluble ligand RANKL on osteoclast precursor cells and induce osteo-
clast differentiation and activation.MAPK: mitogen-activated protein ki-
nase; CRMO: chronic recurrent multifocal osteomyelitis; Erk1: extracel-
lular signal-regulated kinase-1; TLR: Toll-like receptor; IL: interleukin;
JNK: Jun kinase; TNF: tumor necrosis factor; NF-κB: nuclear factor-κB;
Casp1: caspase-1; PAMP: pathogen-associated molecular pattern;
DAMP: danger-associated molecular pattern; RANK: receptor activator
of nuclear factor-κB; RANKL: RANK ligand
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was enhanced in monocytes from CRMO patients, likely due
to reduced DNA methylation of IL20 [41••]. The expression
of other MAPK-induced pro-inflammatory cytokines includ-
ing TNFα and IL-6 was not reduced but rather increased in
monocytes from CRMO patients (Fig. 4b). This may at least
partially be explained by the fact that the alternative p38
MAPK pathway was not affected [42].
Recently, inflammatory bone loss and synovial inflamma-
tion in IL-10-deficient mice were linked to NLRP3
inflammasome activation [44•]. Furthermore, Scianaro et al.
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[45] suggested increased NLRP3 inflammasome activation
contributing to the inflammatory phenotype in CRMO, show-
ing increased mRNA expression of inflammasome compo-
nents (ASC, NLRP3, caspase-1) as well as increased IL-1β
transcription and release from peripheral blood mononuclear
cells from active CRMO patients compared to patients with
inactive disease and controls after stimulation with LPS. We
recently linked impaired IL-10 and IL-19 expression with in-
creased IL-1βmRNA expression and IL-1β release in mono-
cytes from CRMO patients [41••]. Enhanced inflammasome
activation and IL-1β secretion by monocytes from CRMO
patients is reversible by co-culture with recombinant IL-10
or IL-19 [41••], suggesting an immunomodulatory function
of IL-10 and IL-19 on inflammasome activation.
These observations resulted in the hypothesis that imbal-
anced expression of anti- (IL-10 and IL-19) and pro-
inflammatory cytokines (IL-1, IL-6, TNFα, IL-20) may result
in increased osteoclast differentiation and activation through
enhanced interaction between receptor activator of nuclear
factor-κB (RANK) and its soluble ligand RANKL on osteo-
clast precursor cells (Fig. 3) [9, 46, 47].
In addition to the molecular mechanisms mentioned above,
IL-10 expression is predetermined by genetic variants within
the IL10 proximal promoter region. Three promoter haplo-
types rs1800896, rs1800871, and rs1800872, resulting in
three haplotype blocks (GCC, ACC, and ATA), influence the
capacity of the IL10 promoter to recruit the transcription factor
Sp-1. Interestingly, and to our initial surprise, in cohorts of
CRMO patients, IL10 promoter haplotype blocks encoding
for “high” IL-10 expression (GCC) were significantly more
common when compared to such encoding for “low” gene
expression (ATA) [48]. Provided the molecular pathologic
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Fig. 4 Inflammation marker expression in monocytes from CRMO
patients. Monocytes from treatment-naive CRMO patients (N = 17) and
age and gender matched healthy controls (N = 17) were isolated by
negative selection of CD14+ cells using standard procedures (Miltenyi).
Monocytes were cultured at 1 × 106 per milliliter media (RPMI,
gentamycine, penicillin) with 5% CO2 at 37 °C. Some cells were
stimulated with 100 ng/mL LPS over night as indicated. Protein levels
were measured from cell culture supernatants on the LUMINEX2000
platform, using multiplex gene expression arrays (Millipore). a
Monocytes from CRMO patients fail to express immune regulatory
proteins GM-CSF (under resting conditions), IL-10 (under resting
conditions and after stimulation with LPS), and IL-1RA (in response to
stimulation with LPS). b Monocytes from CRMO express increased
levels of pro-inflammatory IL-1b, IL-6, and TNFα (under resting
conditions and in response to stimulation with LPS). c and d
Monocytes from CRMO patients express increased amounts of pro-
inflammatory chemokines IL-8, MCP-1, MIP-1a, and MIP-1b under
resting conditions, MIG in response to stimulation with LPS, and IP-10
under resting conditions and in response to stimulation with LPS. These
observations further indicate a significant imbalance in the expression of
pro- and anti-inflammatory proteins, suggesting a pro-inflammatory
phenotype of monocytes in CRMO which show signs of “spontaneous”
activation
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mechanisms discussed above, we hypothesized that individ-
uals with CRMO-associated molecular disturbances and IL10
promoter haplotype blocks encoding for “low” IL-10 expres-
sion may develop more severe disease and may not be diag-
nosed with CNO/CRMO but other inflammatory conditions.
However, this hypothesis remains to be confirmed
scientifically.
Recently, a CRMO susceptibility gene has been identified
through whole exome sequencing and gene expression micro-
arrays [49]. One homozygous and one compound heterozy-
gous mutation in the filamin-binding domain of the FBLIM1
gene were detected in unrelated CNO patients from South
Asia [49]. Filamin-Binding LIM Protein 1 (FBLIM1) has
been suggested to act as an anti-inflammatory molecule that
controls bone remodeling through the regulation of RANKL
activation via ERK1/2 phosphorylation [49]. On the transcrip-
tional level, FBLIM1 expression is regulated by the transcrip-
tion factor STAT3 [49]. Since the immune regulatory cytokine
IL-10 induces STAT3 activation, aforementioned haplotype
blocks within the IL10 promoter may be involved in the path-
ophysiology of CNO. Indeed, Cox et al. demonstrated that
both individuals carried such IL10 promoter haplotypes that
code for “low” IL-10 expression, whichmay in turn contribute
to reduced STAT3 activation and resulting effects on FBLIM1
expression in the reported individuals [50••].
Biomarkers for the Diagnosis and Monitoring
of CRMO
Currently, widely accepted disease biomarkers for the diagno-
sis of CNO/CRMO are not available. Recently, we reported a
preliminary set of serum inflammatory parameters that allow
differentiating between newly diagnosed and treatment naïve
patients with CRMO, Crohn’s disease, and healthy controls.
Biomarkers included the monocyte derived chemokines mono-
cyte chemotactic protein (MCP-)1 and macrophage inflamma-
tory protein (MIP-)1b, the pro-inflammatory cytokines IL-6
and IL-12, the mast cell derived chemokine eotaxin,
RANTES, the soluble IL-2 receptor, and the IL-1 receptor an-
tagonist. Increased serum levels of the inflammatory cytokines
IL-6 and IL-12, the chemokines MCP-1, MIP-1b, RANTES,
and eotaxin, and the soluble IL-2 receptor distinguished among
CRMO patients, individuals with Crohn’s disease and healthy
controls. However, the proposed set of biomarkers could not
distinguish between patients with CRMO or ANA-positive,
HLA B27-negative juvenile idiopathic arthritis (JIA). This
may be caused by pathophysiological parallels between the
two disorders and/or a currently incomplete set of tested param-
eters [51]. Currently, follow-up studies are under way, includ-
ing additional parameters and differential diagnoses.
In addition to serum biomarkers, cytokine and chemokine
expression from isolated immune cells may be used to
diagnose CNO/CRMO. In Fig. 4, cytokine and chemokine
expression patterns from ex vivo isolated peripheral blood
monocytes from CRMO patients and controls are provided.
Indeed, monocytes from CRMO patients fail to express gran-
ulocyte monocyte colony-stimulating factor (GM-CSF), and
the anti-inflammatory molecules IL-10 and IL-1 receptor an-
tagonist (IL-1RA) under resting conditions and/or in response
to TLR4 stimulation with LPS (Fig. 4a). Conversely, mono-
cytes from CRMO patients express increased amounts of pro-
inflammatory cytokines (IL-1β, IL-6, TNFα; Fig. 4b) and
chemokines (IL-8, Interferon gamma-induced protein 10: IP-
10, MCP-1, MIG, MIP-1a, MIP-1b; Fig. 4c, d) in most cases
already under resting conditions. These findings support pre-
vious reports on dysbalanced cytokine and chemokine expres-
sion and promise potential as disease biomarkers for the diag-
nosis of CNO/CRMO [41••, 42, 43, 51]. However, additional
studies are needed to confirm findings, to extend beyond in-
cluded differential diagnoses, and to generate longitudinal da-
ta sets measuring treatment responses.
Lastly, gene expression profiles in situ may be used as dis-
ease biomarkers. Preliminary studies in bone biopsies from
patients with CRMO, Langerhans cell histiocytosis (LHC),
bacterial osteomyelitis (BOM), or from healthy controls deliv-
ered promising results. In agreement with the aforementioned
observations in ex vivo isolated monocytes, IL-10 expression
in bone tissue from CRMO patients appears reduced when
compared to other inflammatory conditions (LHC and BOM;
Fig. 5). Expression of the inflammasome component NLRP3
and the pro-inflammatory cytokine IL-1β is increased in sam-
ples from CRMO patients when compared to LHC patients or
healthy controls. Patients with BOM, however, (not surprising-
ly) exhibit even higher inflammasome activation and IL-1β
expression levels when compared to CRMO (Fig. 5).
Murine Models of CRMO
Studies in primary human cells and in cell lines are limited by
intrinsic and/or extrinsic factors, including sample sizes, avail-
ability (in primary human cells), culturing conditions, and
biological limitations in immortalized cells. Several murine
models are available to study underlying pathologic mecha-
nisms of non-infectious bone inflammation. Mice deficient of
proline-serine-threonine phosphatase-interacting protein 2
spontaneously develop bone inflammation, elevated pro-
inflammatory cytokines in the blood, extramedullary hemato-
poiesis and skin inflammation, resembling very severe
CRMO (Table 1).
Lupo mice carry a chemically induced homozygous muta-
tion (c.Y180C; p.I282N) in the proline-serine-threonine
phosphatase-interacting protein 2 (Pstpip2) gene [52, 53].
Chronic multifocal osteomyelitis (cmo) mice carry a sponta-
neously acquired homozygous mutation (c.T293C, p.L98P) in
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Fig. 5 Histomorphological appearance of bone inflammation in CNO/
CRMO, bacterial osteomyelitis (BOM), and Langerhans cell histiocytosis
(LCH). Formalin-fixed, decalcified, and paraffin-embedded bone biopsy
specimens were immune-stained with antibodies directed against CD14
(monocyte marker), NLRP3, IL-1β, and IL-10 using standard techniques
(as indicated). Displayed magnification is ×100. In the top panel, HE
stains are displayed. Control: trabecular bone with fatty marrow and
hematopoietic tissue from a bone healthy patient undergoing osteotomy.
CRMO: moderately dense infiltrate of inflammatory cells, predominantly
neutrophils and monocytes, some marrow fibrosis. BOM: dense infiltrate
of inflammatory cells with predominant neutrophils, cellular bone
remodeling and bone necrosis. LCH: Ovoid Langerhans cells, some
with linear grooves of nuclei, admixed with inflammatory cells,
including a large number of eosinophils, lymphocytes, neutrophils, and
plasma cells. Infiltrates of CD14-positive monocytes are a central
component of inflammation in acute BOM, early phase CRMO, and
LCH. Expression of the inflammasome component NLRP3 is increased
in inflammatory infiltrates of BOM> CRMO > LOM, translating into IL-
1 β protein expression in BOM and CRMO. As suggested by studies in
ex vivo isolated monocytes, IL-10 expression in inflammatory bone
lesions from CRMO patients is reduced as compared to lesions from
BOM and LCH patients
Table 1 Pstpip2 mutant mice strains as disease models for CRMO. cmo chronic multifocal osteomyelitis, ENU N-ethyl-N-nitrosourea, Pstpip2
proline-serine-threonine phosphatase-interacting protein 2
Pstpip2 mutant mice Generation Mutation References
lupo mice ENU mutagenesis, homozygous mutation p.I282N
c.Y180C
[52, 53]
cmo mice Homozygous spontaneous mutation p.L98P
Exon5: c.T293C
[26, 54, 28, 55, 56]
Targeted knockout Conventional knockout
Conditional knockout
Target exons 3 and 4 [57]
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Pstpip2. To date, the exact molecular contribution of Pstpip2
mutations to sterile bone inflammation remains somewhat un-
clear [57]. Pstpip2 belongs to the F-BAR (Fes/CIP4 homolo-
gy-Bin/Amphiphysin/Rvs) domain containing protein super-
family, which couples membrane remodeling with actin dy-
namics associated to endocytic pathways and filopodium for-
mation [58]. It is a cytosolic, cytoskeleton-associated adapter
molecule, which interacts with formin binding protein 17
(FBP17) through its F-BAR domain. In the presence of
Pstpip2, an antagonistic recruitment of FBP17 and Pstpip2
to the plasma membrane enables correct activation of actin
polymerization at podosomes. In the absence of Pstpip2, actin
polymerization is hyperactivated by constitutive membrane
recruitment of the FBP17-WASP (Wiskott-Aldrich
syndrome protein) complex [59]. Macrophages that express
Pstpip2 at reduced levels exhibit abnormal podosome forma-
tion, leading to a more invasive phenotype.
Interleukin-1β has been linked with the pathogenesis of
osteomyelitis in cmo mice [60, 61••]. Cmo mice lacking the
functional IL-1 receptor I (IL-1RI) or IL-1β (but not IL-1α)
were completely protected from CNO [60, 61••]. Conversely,
cmo mice deficient of the inflammasome components
NLRP3, ASC or caspase-1 developed severe CNO, indicating
that there must be another kinase or protease other than
caspase-1-activating IL-1β. Previously described proteases,
performing IL-1β cleavage includes neutrophil serine prote-
ases or caspase-8 [62••], suggesting that neutrophils may play
a central role in disease pathogenesis. Thus, Cassel et al. per-
formed experiments to identify immune cell subsets critical
for IL-1β release in cmo mice [60]. LPS-primed and ATP-
stimulated bone marrow cells but not bone marrow derived
macrophages from cmo mice produced high amounts of IL-
1β. Increased IL-1β production was reduced by treatment of
cmo bone marrow with a serine protease inhibitor
(diisopropylfluorophosphate) but not with the pan-caspase-1
inhibitor z-YVAD-fmk [60], suggesting the involvement of
neutrophils in the pathogenesis of cmo. Findings were con-
firmed by Lukens et al. [61••], who additionally showed that
pharmacological depletion of neutrophils with the monoclonal
antibody anti-Ly6G protected cmo mice from CNO [63•].
Interestingly, cmo mice either deficient of caspase-1 or -8 de-
veloped CNO, whereas cmo mice deficient of both caspases
were protected from disease [63•], indicating that both
caspases play redundant roles in cmo mice.
NSAIDs
(e.g. Naproxen) 
Clinical monitoring; 
MRI after 3-6 months
Remission
(at 3 months: ~25% full, ~75% partial, 
at 6 months: ~50% full, ~30% partial remission)
Clinical monitoring; 
MRI after 3-6 months
Corticosteroids + NSAIDs
( 2mg/kg/day over 5-10 days)
Noremission
Corticosteroids + 
NSAIDs
Clinical monitoring; 
MRI after 3-6 months
Remission
Bisphosphonates
(at 3 months ~50% full, 
~50% partial remission; 
at 6 months ~70% full, 
~25% partial remission) 
TNF-blockers
(at 3 months ~40% full,
~30% partial remission;
at 6 months ~80% full, 
~20% partial remission)
Sulfasalazine
MTX
(no reliable data
on remission 
rates)
Severe manifestations
(e.g. arthritis, involvement of the 
gut, the skin or the vertebral  
column, and so on)
Anti-IL1 agents?
Best medication? 
Duration of treatment? 
Remission
(at 3 months: ~30% full, ~50% partial, 
at 6 months: ~35% full, ~35% partial remission)
Fig. 6 Treatment of CNO/CRMO. NSAIDs (e.g., naproxen) are usually
applied as first-line therapy in CNO/CRMOpatients. Monitoring includes
clinical investigations andMRI scans after 3 to 6months. Treatment goals
are clinical and, in the case of vertebral involvement, radiological
remission. In NSAID-refractory cases, treatment can be escalated with
corticosteroids. The authors usually apply 2 mg/kg oral prednisone per
day plus NSAIDs over 5 to 10 days. In cases who first respond to
corticosteroid treatment but then flare, high-dose steroids (2 mg/kg/day)
can be repeated and supplemented by low-dose corticosteroids (0.1–
0.2 mg/kg/day) over a longer period, e.g., to “bridge” until DMARDs
are working. In individuals who fail to reach clinical and (if vertebrae are
involved) radiological remission or relapse again, bisphosphonates,
TNFα inhibitors, sulfasalazine, or methotrexate (MTX) should be
considered. In patients with vertebral body involvement and structural
damage, aggressive treatment should be discussed initially, e.g., with
bisphosphonates
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Taken together, in agreement with aforementioned findings
in monocytes from CRMO patients, recent work in cmo mice
suggests a central involvement of IL-1β in disease pathophys-
iology. Complete deficiency of Pstpip2 results in dysregulated
production of IL-1β by neutrophils and enhanced osteoclas-
togenesis. Of note, myeloid cells determine the phenotype in
Pstpip2-deficient animals (at least initially) independent of the
adaptive immune system [54].
Over the recent years, it became increasingly clear that
host interactions with skin and gut microbiota have signif-
icant effects on immune homeostasis [64]. Particularly in
genetically predisposed individuals, alterations to
microbiomes can result in uncontrolled inflammation and
the expression of autoimmune/inflammatory conditions.
Recent data from Lukens et al. [63•] suggest that dietary
manipulation of the microbiome in cmo mice can prevent
osteomyelitis. The exact molecular mechanisms involved,
however, remain unclear. Patients with CRMO exhibit as-
sociations with severe acne (10%) and inflammatory bowel
disease (10%) [7], which underscores the therapeutic po-
tential of these observations, since all of these CRMO-
associated disorders are characterized by significant alter-
ations to microbiomes [64].
Treatment and Monitoring
Treatment of patients with CNO/CRMO is largely based on
expert opinion and relatively small case collections. It usually
involves non-steroidal anti-inflammatory drugs (NSAIDs),
corticosteroids, disease-modifying anti-rheumatic drugs
(DMARDs, usually methotrexate or sulfasalazine), anti-TNF
agents, or bisphosphonates (Fig. 6).
Several retrospective analyses and one prospective obser-
vation indicate that NSAIDS are effective in a large subset of
patients within the first 1–2 years of treatment. We, however,
recently documented that more than 50% of patients flare after
2 years [7, 65•]. Corticosteroids appear to quickly and effec-
tively control inflammatory activity, but rarely induce long-
term remission. Though only reported in a small number of
patients, treatment with pamidronate or anti-TNF agents has
been reported to be highly effective in a significant percentage
of CNO/CRMO patients, inducing long-lasting remission in a
large subset of patients [3, 9, 66]. However, all reports are
limited by retrospective data collection and relatively small
patient numbers.
Large prospective clinical trials to determine the best med-
ication and the duration of treatment are lacking. Currently,
consensus treatment plan initiatives of the North American
Childhood Arthritis and Rheumatology Research Alliance
(CARRA) and the German Socie ty of Pedia t r ic
Rheumatology (GKJR) are under way and will investigate
and compare treatment responses to currently used therapeutic
agents and protocols.
In addition to the currently applied treatment options,
blockade of other molecules may be beneficial in CNO/
CRMO. Since IL-1β is involved in the molecular patho-
physiology of CNO/CRMO, recombinant IL-1 receptor an-
tagonist anakinra or anti-IL-1 antibody treatment with
canakinumab may be applied. Furthermore, IL-1 blockade
proved effective in familial monogenic autoinflammatory
disorders involving CNO (namely, Majeed syndrome and
DIRA) [32, 35]. However, surprisingly few cases of anti-
IL-1 treatment have been reported and showed mixed re-
sponse with variable outcomes. The potential explanation
for the poor response may include low tissue concentra-
tions, pathophysiological heterogeneity in CNO/CRMO,
among others.
Blockade of RANKL with the recombinant RANK ligand
inhibitor denosumab may reduce osteoclast activation and in-
flammatory bone loss in CNO/CRMO and promises potential
in the treatment of CNO/CRMO. However, at this point, there
are no reliable reports on successful application of these treat-
ment options in CNO/CRMO.
Monitoring disease activity is a concern in CNO/CRMO
patients, since a significant subset of patients may develop
pain amplification syndrome. Thus, clinical scores includ-
ing pain scores, routine inflammatory parameters, and im-
aging results have been suggested (PedCNO score) [66].
However, to date, scores are incompletely evaluated and
involve time consuming and costly investigations (e.g.,
MRI). Thus, easily accessible and inexpensive disease bio-
markers for the assessment of disease activity are urgently
warranted. We recently reported a preliminary set of bio-
markers (IL-12, MCP-1, sIL-2R) that may act as markers
for treatment response to NSAIDs [51]. Though included
as a parameter in PedCNO scores, ESR and CrP correlated
less closely with PedCNO scores when compared to the
reported serum biomarkers. Thus, after further evaluation
in independent cohorts and in response to other treatment
options, IL-12, MCP-1, and/or sIL-2R may be used as fu-
ture biomarkers for disease activity in CNO/CRMO.
Conclusions
Chronic non-bacterial osteomyelitis with its most severe form
chronic recurrent multifocal osteomyelitis is an inflammatory
bone disorder that can result in damage to bones and other
tissues. Due to the lack of widely accepted diagnostic criteria
or disease biomarkers, CNO/CRMO remains a diagnosis of
exclusion. The molecular pathophysiology of CNO/CRMO
remains incompletely understood. However, dysregulated cy-
tokine expression from innate immune cells centrally contrib-
utes to the inflammatory phenotype of CNO. Treatment is
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largely based on small, mostly retrospective case collections
and expert opinion, and prospective studies are largely lack-
ing. Currently, consensus treatment protocols are under way
and will deliver reliable data on treatment responses and out-
comes. The recent identification of several genetic and molec-
ular alterations in CNO/CRMO promise future success in de-
termining exact pathophysiological causes and target-directed
treatment options.
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